Company news

Tiziana Life Sciences Ltd news in 2020

Tiziana Life Sciences Ltd's news releases, calls and decks from 2020, newest first.

View company

Tiziana Life Sciences PLC (“Tiziana” or “the Company”) - Publication of Prospectus

December 17, 2020

Tiziana Life Sciences PLC (“Tiziana” or “the Company”) - Notification of proposed admission to the Main Market and cancellation of trading on AIM

December 16, 2020

Tiziana Life Sciences to Host Investor Update Call on 2 December 2020 at 4: 15 p.m. ET

November 30, 2020

Tiziana Life Sciences PLC ("Tiziana" or the "Company") - PDMR Dealing

November 17, 2020

Tiziana Life Sciences announces collaboration with Parexel Biotech to conduct phase 1b/2 clinical trial in patients with Crohn’s Disease

November 10, 2020

Tiziana Announces Initiation of Clinical Trial with Covid-19 Patients in Brazil with Nasally Administered Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody

November 1, 2020

Tiziana Life Sciences Announces Timetable of Demerger of Accustem (for holders of Tiziana ADRs)

October 26, 2020

Tiziana Life Sciences Plc (the "Company") - Result of General Meeting

October 1, 2020

Tiziana Life Sciences plc to Conduct a Clinical Study with Nasally Administered Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, for Treatment of COVID-19 Patients in Brazil

September 16, 2020

Tiziana Life Sciences Announces Planned Spin Out of StemPrintER into a New Publicly Listed Company, Accustem Sciences

September 15, 2020

Tiziana Life Sciences Clarifies Reason for Filing an Amended ADS Registration Statement

August 27, 2020

Tiziana Granted a Patent on Methods and Use of Anti-IL-6/IL-6 receptor Monoclonal Antibodies as Prophylactic and Therapeutic Interventions for COVID-19 and other pulmonary diseases

August 23, 2020

Tiziana Granted a Patent on the Use of Milciclib in Combination with Tyrosine Kinase Inhibitors for Treatment of Hepatocellular Carcinoma and other Cancers

August 20, 2020

Tiziana is Pleased to Retain Dr. Napoleone Ferrara to Serve on Its Scientific Advisory Board for an Additional Three-Year Term

August 19, 2020

Tiziana Granted a Patent on Methods and Use of Anti-CD3 Monoclonal Antibodies for Treatment of Crohn’s Disease

August 17, 2020

Tiziana Life Sciences plc Announces Closing of $57.25 Million Offering

August 4, 2020

Tiziana Life Sciences Announces an Expedited Clinical Development Plan for Its Anti-Interleukin-6-Receptor, a Fully Human Monoclonal Antibody, for the Treatment of COVID-19 Patients

August 3, 2020

Tiziana Announces Pricing of U.S. Follow-On Offering of ADSs Raising $57.25 million

August 2, 2020

Tiziana Life Sciences plc: Total Voting Rights

July 30, 2020

Tiziana Life Sciences plc: Early notification of proposed admission to the Official List and cancellation of trading on AIM

July 29, 2020

Exercise of Warrants and Issue of Equity and Total Voting Rights

July 23, 2020

Tiziana Life Sciences plc ("Tiziana" or the "Company") Director Appointment

July 19, 2020

Tiziana Announces Submission of Patent Application on Use of Foralumab, the Only Fully Human Anti-CD3 Monoclonal Antibody, to Enhance Success of CAR-T Therapy

July 15, 2020

Tiziana Life Sciences plc Change to ADS Ratio

July 14, 2020

Tiziana Life Sciences PLC Directorate Change

June 17, 2020

Decks in 2020